Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Actinium Pharmaceuticals, Inc.

Ticker
ATNM
Sector
Industry
Report date
November 16, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight Actinium’s clinical progress, management changes, and market interest in its radiopharmaceutical programs.

Recent developments:
  • Actinium advanced its HER3-targeted radiotherapy in a Phase 1 prostate cancer study, demonstrating ongoing clinical development efforts [N1].
  • The company presented its ATNM-400 next-generation radiotherapy approach at EANM 2026, showcasing innovation in its pipeline [N4].
  • Actinium named Matt David as CFO in October 2026, reflecting recent management updates [N5].
  • The company continues its R&D focus amid financial progress, maintaining clinical and operational momentum [N6].
  • Actinium’s stock was noted among biotech sector rallies in late 2026, indicating market recognition of its developments [N2][N3][N7].
Overview

Actinium Pharmaceuticals is focused on developing first-in-class targeted radiopharmaceutical therapeutics that leverage tumor biology and radiochemistry to treat solid tumors and hematologic cancers. The company’s pipeline includes ATNM-400, a novel non-PSMA targeting radioconjugate with pan-tumor potential in prostate, lung, and breast cancers; Actimab-A, targeting CD33+ MDSCs to enhance checkpoint inhibitor efficacy; and conditioning agents Iomab-B and Iomab-ACT for bone marrow transplant and cell/gene therapies. The company has conducted extensive clinical trials involving over 500 patients and is establishing internal manufacturing capabilities to support clinical and commercial supply. Intellectual property protection is robust with approximately 250 patents and applications. Actinium is actively pursuing strategic partnerships to advance late-stage programs and expand its pipeline [S1].

Executive summary

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering targeted radiotherapies for oncology, focusing on novel, biology-driven radiopharmaceuticals for solid tumors and hematologic malignancies. Its pipeline includes ATNM-400, Actimab-A, Iomab-B, and Iomab-ACT, with multiple clinical trials underway and a manufacturing facility expected operational in 2H 2026. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. As of September 30, 2026, the company reported $28.7 million in cash and equivalents, $35 million in revenue, and a net loss of $5.84 million for the quarter, with liquidity ratios indicating a strong current ratio of 4.0 and cash ratio of 3.89 [S2].

Scenarios for ATNM

Bull case model:

The company’s differentiated pipeline targeting novel antigens with pan-tumor potential and synergy with existing therapies could address significant unmet medical needs in oncology. Successful clinical trial execution and strategic partnerships could advance late-stage hematology programs toward regulatory approval. The establishment of internal manufacturing capabilities may enhance supply reliability and cost efficiency. Continued innovation and pipeline expansion could position Actinium as a leader in targeted radiotherapy [S1][N1][N4].

Bear case model:

Actinium faces risks typical of clinical-stage biopharmaceutical companies, including the absence of approved products and reliance on successful clinical and regulatory outcomes. The FDA has required additional trials for Iomab-B, delaying potential approval and commercialization. The company has a history of net losses and depends on raising additional capital, which may be challenging under market conditions. Key personnel dependence and competitive pressures in the radiopharmaceutical space add to execution risks. Manufacturing and regulatory complexities inherent to radiopharmaceuticals may also pose challenges [S2].

Moat:

Actinium’s moat is built on its biology-driven approach to radiopharmaceutical development targeting novel antigens not addressed by competitors, supported by a broad and differentiated pipeline spanning solid tumors and hematology. Its extensive clinical trial experience, end-to-end supply chain management, and proprietary manufacturing capabilities, including an upcoming internal cGMP facility, provide operational advantages. The company’s substantial intellectual property portfolio covering composition of matter and production technologies creates barriers to entry. Strategic partnerships and FDA alignment on trial designs further strengthen its competitive position [S1].

Risks overview
Risks summary
The most significant risks include clinical and regulatory uncertainties for pipeline candidates, financial dependence on capital markets, and the FDA’s additional requirements for Iomab-B approval, which may delay or prevent commercialization.
Risks details:

• Clinical and Regulatory Risk: None of Actinium’s product candidates have received regulatory approval. Clinical trials may fail to demonstrate safety and efficacy, delaying or preventing approval and commercialization [S2].
• Financial Risk: The company has incurred net losses historically and expects to continue incurring losses. It depends on raising additional capital to fund operations, which may not be available on favorable terms or at all [S2].
• Dependence on Key Personnel: Actinium is highly dependent on its CEO and other key management. Loss of key personnel could disrupt business operations and strategy execution [S2].
• Manufacturing and Supply Chain Risk: Radiopharmaceutical manufacturing is complex and subject to supply chain risks. While the company is establishing internal manufacturing, disruptions could adversely affect clinical and commercial supply [S1][S2].
• Regulatory and Market Uncertainty for Iomab-B: The FDA requires additional trials for Iomab-B to demonstrate overall survival benefit and dose optimization, creating uncertainty around approval and commercialization, especially in the U.S. market [S2].

FINAL FORECAST FOR ATNM

Final take one line
Actinium Pharmaceuticals exhibits very high visibility with a differentiated radiopharmaceutical pipeline, robust clinical and manufacturing capabilities, and clear regulatory and financial risks typical of clinical-stage biotech companies.
Final take 12 to 24 month view

Business trends: Continued clinical development of novel radiopharmaceuticals targeting solid tumors and hematologic malignancies, with increasing market interest in targeted radiotherapy.
Execution milestones: Advancement of ATNM-400 and Actimab-A clinical trials, commissioning of internal manufacturing facility, and securing strategic partnerships for late-stage programs.
Key risks: Clinical and regulatory uncertainties, capital raising challenges, dependence on key personnel, and FDA requirements for additional trials on Iomab-B.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapies for oncology, addressing unmet medical needs in solid tumors and hematologic malignancies [S1].
  • The company employs a biology-driven approach to develop differentiated, first-in-class radiopharmaceutical therapeutics combining tumor biology understanding with radiochemistry expertise [S1].
  • Its pipeline includes solid tumor candidates ATNM-400 and Actimab-A, and hematology programs Iomab-B and Iomab-ACT, with Actimab-A and Iomab-B being Phase 2/3 ready [S1].
  • ATNM-400 targets a novel, non-PSMA antigen with preclinical activity in metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer, showing pan-tumor potential [S1].
  • Actimab-A targets CD33+ myeloid derived suppressor cells (MDSCs) and is studied in combination with PD-1 inhibitors in multiple solid tumors, addressing PD-1 resistance mechanisms [S1].
  • Iomab-B and Iomab-ACT are targeted conditioning agents for bone marrow transplant and cell/gene therapies, with Iomab-B having FDA alignment on Phase 2/3 trial design [S1].
  • The company has conducted clinical trials involving over 500 patients and operates an end-to-end supply chain including isotope sourcing, manufacturing, and drug delivery to approximately 50 treatment centers [S1].
  • Actinium is establishing an internal cGMP radiopharmaceutical manufacturing facility expected operational in second half of 2026 to support clinical supply and commercial scale [S1].
  • The company holds approximately 250 issued and pending patents covering composition of matter, methods of use, and proprietary Ac-225 production technology, providing substantial IP protection [S1].
  • Financial snapshot as of September 30, 2026: cash and equivalents $28.7 million, current assets $29.5 million, current liabilities $7.37 million, revenue $35 million, net loss $5.84 million, basic and diluted EPS -$0.19; liquidity ratios include current ratio 4.0 and cash ratio 3.89 [S2].
  • The company reported net income of $16.5 million for the nine months ended September 30, 2026, primarily due to recognition of $35 million revenue from a commercialization agreement, but historically has incurred net losses and expects to continue incurring losses [S2].
  • Actinium is highly dependent on the clinical, regulatory, and commercial success of its pipeline candidates, including ATNM-400, Actimab-A, and Iomab-ACT, which have not yet received regulatory approval [S2].
  • The company is actively seeking strategic partnerships to advance late-stage hematology programs and to support global pivotal trials [S1].
  • Key personnel include CEO Sandesh Seth, who holds significant institutional knowledge and patent inventorship; recent management changes include appointment of a new CFO in October 2026 [S2][N5].
  • Recent news highlights include advancement of HER3-targeted radiotherapy in Phase 1 prostate cancer study, presentation of ATNM-400 radiotherapy approach at EANM 2026, and continued R&D focus amid financial progress [N1][N4][N6].
  • The company’s stock has been noted in biotech sector rallies in 2026, reflecting market interest in its developments [N2][N3][N7].
Sources
Sources - Context summary

Generated 2026-11-17

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-30 | 10-K
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-10-23 | www.nasdaq.com | Actinium Advances HER3-Targeted Radiotherapy In Phase 1 Prostate Cancer Study | https://www.nasdaq.com/articles/actinium-advances-her3-targeted-radiotherapy-phase-1-prostate-cancer-study
  • N2 | 2026-10-22 | www.nasdaq.com | Biotech Stocks Rally: BHVN Jumps 31%, KRRO Climbs 25%, ATNM And VCRE Gain | https://www.nasdaq.com/articles/biotech-stocks-rally-bhvn-jumps-31-krro-climbs-25-atnm-and-vcre-gain
  • N3 | 2026-10-19 | www.nasdaq.com | Biotech Stocks Rally: SLN Soars 125%, WORX Jumps 105%, IRON Gains 41% | https://www.nasdaq.com/articles/biotech-stocks-rally-sln-soars-125-worx-jumps-105-iron-gains-41
  • N4 | 2026-10-19 | www.nasdaq.com | Actinium Brings ATNM-400's Next-Generation Radiotherapy Approach To EANM 2026 | https://www.nasdaq.com/articles/actinium-brings-atnm-400s-next-generation-radiotherapy-approach-eanm-2026
  • N5 | 2026-10-15 | www.nasdaq.com | Actinium Pharmaceuticals Names Matt David CFO | https://www.nasdaq.com/articles/actinium-pharmaceuticals-names-matt-david-cfo
  • N6 | 2026-03-31 | www.nasdaq.com | Actinium Pharmaceuticals Continues R&D Focus Amid Financial Progress | https://www.nasdaq.com/articles/actinium-pharmaceuticals-continues-rd-focus-amid-financial-progress
  • N7 | 2026-01-13 | www.nasdaq.com | After-Hours Biotech Rally: FBLG, NYXH, FBIO, RVTY, OPCH, ATNM, DSGN Climb On Earnings And Momentum | https://www.nasdaq.com/articles/after-hours-biotech-rally-fblg-nyxh-fbio-rvty-opch-atnm-dsgn-climb-earnings-and-momentum
  • N8 | 2025-12-22 | www.nasdaq.com | Are Medical Stocks Lagging Actinium Pharmaceuticals (ATNM) This Year? | https://www.nasdaq.com/articles/are-medical-stocks-lagging-actinium-pharmaceuticals-atnm-year
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine